9 Facts About Ashwagandha and What the Evidence Actually Shows for Menopause, Cortisol, and Sleep
When the sleepless nights and wired-but-exhausted feeling hit, ashwagandha was the first thing half a dozen people recommended. The appeal makes complete sense — it sounds natural, it sounds ancient, and it sounds like it fixes exactly the right things. What took longer to find was an honest breakdown of what the trials actually tested, on whom, and at what dose. That's what this page tries to be.
Learn more about Rose →Ashwagandha is an adaptogen with a real mechanism — it's not just herbal folklore
Ashwagandha (Withania somnifera) contains active compounds called withanolides that appear to modulate the hypothalamic-pituitary-adrenal (HPA) axis, the body's central stress-response system. This is the same axis that goes haywire during perimenopause as estrogen fluctuates, which is part of why the supplement gets so much attention in this space. The mechanism is biologically plausible, not imaginary — but a plausible mechanism doesn't automatically mean a proven clinical outcome.
The strongest evidence for ashwagandha is in stressed, non-menopausal adults — not specifically menopausal women
The most cited ashwagandha RCTs recruited generally healthy but chronically stressed adults, typically aged 18–65, with no specific focus on hormonal status or menopausal stage. A well-known 2019 trial in the Journal of Medicine found significant reductions in serum cortisol and perceived stress scores compared to placebo — but the participants were not screened for perimenopause or menopause. Extrapolating these results directly to menopausal women is reasonable as a hypothesis, but it hasn't been confirmed in dedicated trials.
There is exactly one small RCT focused on ashwagandha in menopausal women — and it showed promising but limited results
A 2021 pilot RCT published in the Journal of Obstetrics and Gynaecology Research followed 91 perimenopausal women taking 300mg of ashwagandha root extract twice daily for eight weeks. Participants reported statistically significant improvements in hot flashes, sleep quality, and anxiety compared to placebo, with no serious adverse events. The trial was small, short, industry-adjacent in funding, and used a single proprietary extract — so it's a genuinely encouraging signal, not a settled conclusion.
Ashwagandha does appear to lower cortisol — but 'lower cortisol' is not the same as 'fixes menopause symptoms'
Multiple RCTs have shown statistically significant reductions in serum and salivary cortisol in participants taking ashwagandha root or leaf extracts, typically in the range of 14–32% reduction versus placebo over 8–12 weeks. Elevated cortisol does contribute to sleep disruption, weight redistribution, and mood changes that overlap with perimenopause symptoms, so reducing it is genuinely relevant. However, many of the most disruptive menopause symptoms — hot flashes, vaginal dryness, bone loss — are driven primarily by estrogen decline, not cortisol, and ashwagandha does not address those pathways.
The sleep evidence is real but modest — it works better for stress-related insomnia than hormonal waking
A 2020 meta-analysis of five RCTs found ashwagandha produced small but statistically significant improvements in sleep onset latency, total sleep time, and sleep quality scores compared to placebo. The effect was strongest in people whose poor sleep was associated with high perceived stress and elevated cortisol — which describes a meaningful subset of perimenopausal women. However, women whose sleep is disrupted primarily by night sweats and vasomotor symptoms are likely to see less benefit, since ashwagandha doesn't meaningfully reduce hot flashes in most of the evidence base.
Dose and extract type matter enormously — and most wellness content ignores this completely
Clinical trials have used doses ranging from 240mg to 600mg per day of root extract, and some have used leaf extract or full-spectrum preparations with very different withanolide concentrations. The proprietary extract KSM-66 and Sensoril appear most frequently in positive trials, but these are specific standardized products — not all ashwagandha supplements are equivalent in composition or potency. When influencers say 'ashwagandha works for sleep,' they're often citing a trial that used a specific extract at a specific dose that may bear little resemblance to the product being promoted.
Ashwagandha has genuine thyroid interactions that matter more in perimenopause than most sources acknowledge
Several studies have shown ashwagandha can increase T3 and T4 thyroid hormone levels, which is sometimes marketed as a benefit but is clinically significant for women with thyroid conditions — a group that overlaps substantially with perimenopausal women, since autoimmune thyroid disease peaks around this life stage. Women already on levothyroxine or managing Hashimoto's should discuss ashwagandha use with their prescriber before starting, as the interaction could alter thyroid hormone balance in ways that affect symptom management. This isn't a reason to avoid it categorically, but it's a real consideration that tends to get glossed over in wellness content.
Safety data is generally reassuring for short-term use, but long-term data in older women is thin
RCTs of up to 12 weeks duration consistently report low rates of adverse events, with the most common being mild gastrointestinal discomfort, and no significant effects on liver enzymes or safety markers in most trials. However, there are case reports of hepatotoxicity (liver injury) associated with high-dose or prolonged ashwagandha use, and post-market surveillance data is limited for women over 50. The current evidence supports cautious short-term use, but women with liver conditions or those taking hepatically metabolized medications should flag it with their healthcare provider.
Ashwagandha is worth considering as a supporting tool — but it isn't a substitute for addressing estrogen decline
For perimenopausal women whose primary struggles are stress reactivity, cortisol-driven sleep disruption, and anxiety layered on top of hormonal change, ashwagandha has enough evidence to be a reasonable, low-risk addition to a broader strategy. What it doesn't do is replace the hormonal work — it won't stop bone density loss, restore vaginal tissue, prevent cardiovascular risk shifts, or reliably resolve vasomotor symptoms in the way that evidence-based hormonal and non-hormonal treatments do. Treating it as a natural alternative to HRT or other proven interventions would mean leaving more effective options on the table.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.